Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT
DRKS00031683Phase 3Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- May 2023
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing Taldefgrobep alfa with Placebo (2 arms). Started May 2023; status: recruiting.
02
Drugs
taldefgrobep alfa
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on DRKS00031683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00031683.